Que es el NOAEL y como se usa?

No Observed Adverse Effect Level. La dosis mas alta en estudios toxicologicos sin efectos adversos observados. Se usa para calcular la dosis inicial en humanos aplicando safety factors (10x para interspecies, 10x para interindividual).

Cuales son los estudios core de safety pharmacology?

Cardiovascular: hERG in vitro, telemetry ECG in vivo. CNS: Irwin test, functional observations. Respiratory: respiratory rate, tidal volume. Identifican riesgos a funciones vitales antes de exposicion clinica.

Se requieren estudios de carcinogenicidad para peptidos?

No siempre. Depende de duracion de tratamiento anticipada y mecanismo de accion. Si el peptido tiene potencial proliferativo o tratamiento >6 meses, puede requerirse. Transgenic models son alternativa a 2-year studies.

Que estudios DART se necesitan?

Fertility (antes de estudios en mujeres), embryo-fetal development (antes de fase III), pre- and postnatal development (para indicaciones cronicas). Rat y rabbit son especies estandar. Timing segun poblacion clinica.

Estudios de Toxicidad Preclinica de Peptidos

Categorías: Metodología de Investigación, Protocolos de Seguridad, Información General

Los estudios toxicologicos preclinicos son obligatorios antes de administrar peptidos a humanos. Identifican riesgos potenciales y establecen margenes de seguridad.

Resumen Simplificado

Toxicidad preclinica incluye single-dose, repeat-dose, genotoxicidad y safety pharmacology en dos especies.

Principios de toxicologia peptidica

Toxicologia evalua riesgo. Safety testing antes de humanos. Tipos de toxicidad. On-target. Relacionada al mecanismo. Exaggerated pharmacology. Off-target. No relacionada al target. Immunotoxicity. ADAs. Hypersensitivity. Immunomodulation. Local tolerance. Injection site reactions. Systemic toxicity. Organ-specific. Peptidos unicos. Species specificity. Receptor binding differs. Cross-reactivity. Not all species relevant. Immunogenicity in animals. ADAs may develop. Affects interpretation. Biological activity. Human vs animal. Selection de especies. Relevant pharmacology. Receptor present. Similar affinity. Toxicologia preclinica es base. Informs clinical safety monitoring.

Estudios de dosis unica

Single-dose toxicity. Primero en desarrollo. Objective. Identify acute toxicity. Dose-limiting effects. Maximum tolerated dose. MTD. Lethal dose. LD50. Not required by modern guidelines. Limit test approach. Fixed high dose. Observe for toxicity. Species. Rodent. Rat. Mouse. Non-rodent. Dog. Non-human primate. Route. Clinical route. IV. SC. IM. Alternative routes for comparison. Dose levels. Multiple levels. Ascending. Identify dose-response. Observation period. 14 days minimum. Clinical signs. Body weight. Food consumption. Mortality. Necropsy. Gross pathology. Histopathology limited. Single-dose estudios dan seguridad aguda. Informan starting dose for clinical.

Estudios de dosis repetidas

Repeat-dose toxicity. Core requirement. Duration. Clinical duration. 1-2 weeks clinical. 1 month toxicology. 1 month clinical. 3 months toxicology. Longer clinical. 6 months toxicology. Rodent. 1, 3, 6 months. Non-rodent. 1, 3, 9 months. ICH M3(R2). Dose levels. High dose. Toxic effects expected. MTD if achievable. Mid dose. Multiple of clinical. Margin of safety. Low dose. No toxicity. Clinical exposure or below. Control group. Vehicle control. Parameters. Clinical observations. Daily. Body weight. Weekly. Food consumption. Weekly. Ophthalmology. Pre-study, end. Clinical pathology. Hematology. Clinical chemistry. Urinalysis. Multiple timepoints. Organ weights. Terminal. Histopathology. Full tissue list. Recovery group. No treatment. Assess reversibility. Repeat-dose define NOAEL. No Observed Adverse Effect Level. Basis for clinical starting dose.

Safety pharmacology

Safety pharmacology evalua funciones criticas. Core battery. Cardiovascular. CNS. Respiratory. ICH S7A. ICH S7B. Cardiovascular. In vitro. hERG assay. IKr current. QT prolongation risk. In vivo. Telemetry. ECG. Blood pressure. Heart rate. Conscious animals. QT interval. Corrected QT. QTc. CNS. Irwin test. Rodent. Functional observations. Motor activity. Coordination. Behavioral changes. Seizure potential. Respiratory. Respiratory rate. Tidal volume. Minute volume. Pulse oximetry. Blood gases. Supplemental studies. If signals. Renal function. Gastrointestinal. Additional endpoints. Integrated in repeat-dose. Standalone studies if needed. Safety pharmacology identifies. Risk to vital functions. Clinical monitoring plan.

Genotoxicidad y carcinogenicidad

Genotoxicidad. ICH S2(R1). Standard battery. Bacterial reverse mutation. Ames test. Salmonella. E. coli. Gene mutations. In vitro mammalian. Chromosome aberration. Mouse lymphoma. Gene mutation. In vivo. Micronucleus test. Rat bone marrow. Mouse peripheral blood. Chromosomal damage. Peptidos. Usually not genotoxic. Metabolites may be. Negative results expected. Carcinogenicidad. Long-term studies. 2 years. Rat. Mouse. Peptidos. Not always required. Duration of treatment. Risk assessment. Mechanism-based. ICH S1. If indicated. Alternative approaches. Transgenic models. 6 months. Mechanistic studies. Proliferative effects. Receptor-mediated. Genotoxicidad is screening. Carcinogenicidad case-by-case.

Toxicidad del desarrollo y reproduccion

DART studies. Developmental and reproductive toxicity. ICH S5(R3). Study types. Fertility. Male. Female. Reproductive performance. Embryo-fetal development. EFD. Teratogenicity. Pre- and postnatal development. PPD. Timing. Before inclusion of women of childbearing potential. Before large populations. Species selection. Rat. Rabbit. Relevant to human. Pharmacology present. Dose selection. Maternal toxicity. Embryo-fetal toxicity. Margin over clinical. Routes of exposure. Clinical route. Duration. Sensitive periods. Organogenesis. Gestation days. Lactation. Endpoints. Maternal. Body weight. Clinical signs. Necropsy. Fetal. Viability. Weight. External malformations. Visceral. Skeletal. PPD. Developmental milestones. Behavior. Reproduction. DART identifies. Risks to reproduction. Labeling implications. Pregnancy categories.

Hallazgos Clave

La seleccion de especies debe considerar relevancia farmacologica (receptor presente, afinidad similar)
Single-dose toxicity identifica MTD y efectos agudos; informan starting dose clinica
Repeat-dose establece NOAEL, base para margen de seguridad y dosis clinica
Safety pharmacology evalua CV (hERG, ECG), CNS (Irwin) y respiratorio
Genotoxicidad standard: Ames, chromosome aberration, micronucleus; peptidos usualmente negativos
DART se requiere antes de incluir mujeres en edad fertil en estudios clinicos

Más artículos en Metodología de Investigación

Más artículos en Protocolos de Seguridad

Preguntas frecuentes

Que es el NOAEL y como se usa?: No Observed Adverse Effect Level. La dosis mas alta en estudios toxicologicos sin efectos adversos observados. Se usa para calcular la dosis inicial en humanos aplicando safety factors (10x para interspecies, 10x para interindividual).
Cuales son los estudios core de safety pharmacology?: Cardiovascular: hERG in vitro, telemetry ECG in vivo. CNS: Irwin test, functional observations. Respiratory: respiratory rate, tidal volume. Identifican riesgos a funciones vitales antes de exposicion clinica.
Se requieren estudios de carcinogenicidad para peptidos?: No siempre. Depende de duracion de tratamiento anticipada y mecanismo de accion. Si el peptido tiene potencial proliferativo o tratamiento >6 meses, puede requerirse. Transgenic models son alternativa a 2-year studies.
Que estudios DART se necesitan?: Fertility (antes de estudios en mujeres), embryo-fetal development (antes de fase III), pre- and postnatal development (para indicaciones cronicas). Rat y rabbit son especies estandar. Timing segun poblacion clinica.

Volver a la biblioteca de investigación